Navigation Links
At-the-Market Offerings (ATM) of Life Sciences Companies Perform Well in Weak Follow-on Financing Environment of Third Quarter
Date:12/13/2011

NEW YORK, Dec. 13, 2011 /PRNewswire/ -- Brinson Patrick Securities Corporation, a boutique investment bank specializing in at-the-market (ATM) offerings, announced today that life sciences companies in the U.S. raised $25 million through activity of nine ATM offerings of common stock in the third quarter of this year.

While the data represent a 60 percent decrease in the use of ATMs in the life sciences sector compared to the second quarter of 2011, this reduction in gross proceeds is less than the 77 percent decline observed with more traditional follow-on financing vehicles such as registered direct, secondary and private investment in public equity (PIPE) offerings.  In addition, four new ATMs were activated in the third quarter, combining for a total of 15 new ATMs through the third quarter.

"The third quarter was a challenging fundraising period across the board for life sciences companies regardless of the fundraising vehicle employed," said Todd Wyche, founder and managing director of Brinson Patrick. "The driver for reduced ATM activity was a weak biotechnology equity market, in which the AMEX Biotechnology Index declined 26 percent during the third quarter.  However, ATMs preformed relatively well compared to conventional follow-on financings because they enable companies to remain in control of their financing activities and raise capital as needed.  We view this as further evidence of the flexibility and value of ATMs as a financing vehicle that should be included in all CFOs' toolboxes."

Life science companies that utilized ATMs to raise capital in the third quarter included AEterna Zentaris Inc., Quebec City, Quebec; OXiGENE Inc., South San Francisco; Apricus Biosciences, Inc., San Diego; and XOMA Ltd., Berkeley, Calif.

An ATM offering provides an efficient means of raising equity capital over time by enabling a publicly traded company to tap into the existing secondary market for its shares on an as-needed basis. With an ATM, an exchange listed company incrementally sells newly issued shares into the trading market through a designated broker-dealer at prevailing market prices, rather than via a traditional underwritten offering of a fixed number of shares at a fixed price all at once.

ATMs raise incremental capital over time, making them ideal for raising general working capital, funding specific projects, funding research and development, and paying off debt. ATM offerings are generally less expensive and less complicated to execute than traditional equity offerings and do not require a lot of executive time – for instance there are no required executive road shows.

"Looking forward, we expect that the life sciences financing environment will remain challenging but that ATMs will continue to perform relatively well and that they will continue to be increasingly recognized as a valuable financing option," added Wyche.

About Brinson Patrick Securities Corporation
Brinson Patrick Securities Corporation is a boutique investment bank that employs a single financing tool, DOCS® (Dynamic Offering of Common Stock) at-the-market (ATM) financing facility, to raise capital for clients as they need it, without the dilution that occurs with more traditional financing vehicles and with little or no impact on the stock price.

The DOCS® ATM is a low-profile equity offering that is appropriate for publicly traded companies across multiple industries and market capitalizations. It has been successfully utilized by companies in the energy, life science, technology, real estate, financial services and hospitality industries with market capitalizations that range from $50 million to over $1 billion. In each case, what makes Brinson Patrick and its specialized offering a fit is a desire on the part of companies to better manage and control the fundraising process. Though Brinson Patrick's experience crosses multiple industries, the firm's life science and real-estate practices are based on a deep understanding of the challenges faced by companies in these industries.

Brinson Patrick is a FINRA member broker-dealer.

 

Media Contacts:

Robert Flamm, Ph.D., and David Schull
Russo Partners
(212) 845-4226
(858) 717-2310
Robert.flamm@russopartnersllc.com  
David.schull@russopartnersllc.com

 

 

 

 


'/>"/>
SOURCE Brinson Patrick Securities Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Contour Products Introduces Groundbreaking Sleep Apnea, Respiratory and Ergonomic Body Comfort Pillows at Medtrade; Self-Explanatory Products Serve Customer Needs, Expand Retailers DME Offerings
2. Simbionix Increases Product Offerings for OB/GYN Physicians
3. Cephalon Prices 5 Million Shares of Common Stock and $435 Million in 2.50% Convertible Senior Subordinated Notes in Public Offerings
4. Onyx Pharmaceuticals Announces Pricing of Concurrent Offerings of Four Million Shares of Common Stock and $200 Million Principal Amount of Convertible Senior Notes
5. Model N Extends its Industry-Leading Contract Management Offerings with Contract Authoring Capabilities
6. Global Trends Drive Opportunities for Tailored Offerings, Market Partnerships and Sustainable Growth
7. Dehaier Medical Systems Extends Product Offerings with Exclusive Distribution Agreement for Penlon Anesthesia System in North China
8. CoreLab Partners Launches New DXA Imaging Service Offerings
9. Transgenomic, Inc. Enhances FAMILION® Genetic Test Offerings
10. Centrify Secures $16M in Financing to Expand Distribution and Extend Its On-Premise and Cloud Security Offerings
11. McKesson Corporation Unveils New Offerings to Empower the Community Patient Care Delivery System
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... , ... December 08, 2016 , ... ... the business of innovation is taking over sports. On Thursday, December 15th a ... how technology is disrupting the playing field at a Smart Talk session. Smart ...
(Date:12/8/2016)... SAN DIEGO , Dec. 8, 2016 /PRNewswire-USNewswire/ ... treatments for congestive heart failure and type 2 ... license for a novel adeno-associated virus (AAV) vector ... Kay , M.D., Ph.D., at Stanford University. The ... of its paracrine gene therapy product pipeline. ...
(Date:12/8/2016)... ... December 08, 2016 , ... ... that provide essential device-to-computer interconnect using USB or PCI Express, announced the FOMD-ACV-A4, ... The FOMD-ACV-A4 is a small, thin, SODIMM-style module that fits a standard 204-pin ...
(Date:12/8/2016)...  Anaconda BioMed S.L., a pre-clinical stage medical device ... neuro-thrombectomy system for the treatment of Acute Ischemic Stroke ... to join its Scientific Advisory Board (SAB). The SAB ... scientific and clinical experts to Anaconda BioMed S.L., as ... ┬« to its clinical phase. The SAB is ...
Breaking Biology Technology:
(Date:11/28/2016)... LONDON , Nov. 28, 2016 ... at a rate of 16.79%" The biometric system ... to grow further in the near future. The biometric ... 32.73 billion in 2022, at a CAGR of 16.79% ... biometrics system, integration of biometric technology in smartphones, rising ...
(Date:11/22/2016)... According to the new market research report "Biometric System Market by Authentication ... (Hardware and Software), Function (Contact and Non-contact), Application, and Region - Global ... from USD 10.74 Billion in 2015 to reach USD 32.73 Billion by ... Continue Reading ... ...
(Date:11/21/2016)... 21, 2016   Neurotechnology , a provider ... today announced that the MegaMatcher On Card fingerprint ... for the NIST Minutiae Interoperability Exchange (MINEX) ... mandatory steps of the evaluation protocol. ... test of fingerprint templates used to establish compliance ...
Breaking Biology News(10 mins):